Tumor News and Research

RSS

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects.

10 May 2013

Sunnybrook Health Sciences Centre signs research agreement to evaluate MRI-guided radiation therapy

Elekta and Royal Philips Electronics announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy.

From Elekta 10 May 2013

Modifications in key epigenetic markers influence human embryonic stem cells

Scientists have long known that control mechanisms known collectively as "epigenetics" play a critical role in human development, but they did not know precisely how alterations in this extra layer of biochemical instructions in DNA contribute to development.

10 May 2013

Researchers discover novel mechanism of tumor hypoxia

An article published recently in Tumor Microenvironment and Therapy - an open access journal by Versita, defines a novel mechanism of tumor hypoxia induced by the longitudinal gradient of residual oxygen along tumor vessels as they transverse the tumor.

10 May 2013

New research from Wake Forest Baptist looks at gene expression profiling in breast cancer

Predicting outcomes for cancer patients based on tumor-immune system interactions is an emerging clinical approach, and new research from Wake Forest Baptist Medical Center is advancing the field when it comes to the most deadly types of breast cancer.

10 May 2013

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.

9 May 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

In cancer, mutations in proteins that control cell growth are common, leading to unrestrained cellular proliferation and tumor formation.

9 May 2013

Meridian Health celebrates Paint the Town Pink to emphasize importance of annual mammography

This May, Meridian Health celebrates Paint the Town Pink - a community-wide effort taking place in 23 Monmouth and Ocean County towns that raises awareness of the importance of annual mammography, as early detection is a woman's best defense against breast cancer.

9 May 2013

Special issue of Gastroenterology presents variety of topics related to pancreas

The editors of Gastroenterology, the official journal of the American Gastroenterological Association Institute, are pleased to announce the publication of this year's highly anticipated special 13th issue.

9 May 2013

Study suggests new application for endovascular grafts

Tumors have the potential to grow locally and invade neighboring organs. Some chest tumors may invade one of the great vessels of the body, the aorta. Surgical removal of these tumors is very challenging and necessitates the support of a heart-lung machine.

9 May 2013

Gene offers new insights into treatment strategies for deep-vein thrombosis

A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis -- the formation of a harmful clot in a deep vein.

9 May 2013

The Avon Foundation awards $275,000 grant to George Washington University

The Avon Foundation announced $275,000 in grants to The George Washington University (GW) School of Medicine and Health Sciences (SMHS) and GW Cancer Institute (GWCI), at the close of the 11th annual Avon Walk for Breast Cancer in Washington, D.C.

8 May 2013

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib.

8 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

Seven-year quest to understand how breast cancer cells resist treatment

A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death.

8 May 2013

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial size, saves money, and may speed test drugs through the drug development pipeline.

8 May 2013

Scientists identify TR4 protein that drives the formation of pituitary tumors in Cushing's disease

Scientists at the Salk Institute for Biological Studies have identified a protein that drives the formation of pituitary tumors in Cushing's disease, a development that may give clinicians a therapeutic target to treat this potentially life-threatening disorder.

8 May 2013

Study shows turning up few microRNAs may offer much anti-breast-cancer activity

A University of Colorado Cancer Center study recently published in the journal Cell Death & Disease shows that turning up a few microRNAs a little may offer as much anti-breast-cancer activity as turning up one microRNA a lot - and without the unwanted side effects.

8 May 2013

Clinical data of cabozantinib to be presented at ASCO meeting

Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.

8 May 2013

Advances in lung cancer treatment have major impact on short- and long-term outcomes

The American College of Chest Physicians third edition of evidence-based lung cancer guidelines, Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, recommends offering low-dose computed tomography scanning for lung cancer screening to people with a significant risk of lung cancer due to age and smoking history.

8 May 2013

Tumor News and Research

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

Sunnybrook Health Sciences Centre signs research agreement to evaluate MRI-guided radiation therapy

Modifications in key epigenetic markers influence human embryonic stem cells

Researchers discover novel mechanism of tumor hypoxia

New research from Wake Forest Baptist looks at gene expression profiling in breast cancer

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

Meridian Health celebrates Paint the Town Pink to emphasize importance of annual mammography

Special issue of Gastroenterology presents variety of topics related to pancreas

Study suggests new application for endovascular grafts

Gene offers new insights into treatment strategies for deep-vein thrombosis

The Avon Foundation awards $275,000 grant to George Washington University

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

Seven-year quest to understand how breast cancer cells resist treatment

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Scientists identify TR4 protein that drives the formation of pituitary tumors in Cushing's disease

Study shows turning up few microRNAs may offer much anti-breast-cancer activity

Clinical data of cabozantinib to be presented at ASCO meeting

Advances in lung cancer treatment have major impact on short- and long-term outcomes

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News